KPG 121
Alternative Names: KPG-121Latest Information Update: 20 Jul 2024
At a glance
- Originator Kangpu Biopharmaceuticals
- Developer Accelovance; Kangpu Biopharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action Angiogenesis inhibitors; CRBN protein modulators; Immunomodulators; Ubiquitin protein ligase complex modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Prostate cancer
- Preclinical Haematological malignancies
Most Recent Events
- 20 Jul 2024 KPG 121 is still in phase I trials for Prostate cancer in the USA (NCT03569280)
- 28 Jun 2024 No recent reports of development identified for phase-I development in Prostate-cancer(Combination therapy, Hormone refractory, Inoperable/Unresectable, Metastatic disease) in USA (PO)
- 10 Jun 2024 Kangpu Biopharmaceuticals plans a phase II/III trial for Prostate cancer (Combination therapy, First line therapy, Hormone refractory)